Cytokinetics (CYTK) Amortization of Deferred Charges (2022 - 2025)
Historic Amortization of Deferred Charges for Cytokinetics (CYTK) over the last 3 years, with Q4 2024 value amounting to $3.5 million.
- Cytokinetics' Amortization of Deferred Charges rose 12595.34% to $3.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.6 million, marking a year-over-year increase of 5745.81%. This contributed to the annual value of $11.6 million for FY2024, which is 5745.81% up from last year.
- Per Cytokinetics' latest filing, its Amortization of Deferred Charges stood at $3.5 million for Q4 2024, which was up 12595.34% from $3.5 million recorded in Q3 2024.
- Cytokinetics' 5-year Amortization of Deferred Charges high stood at $7.1 million for Q3 2023, and its period low was -$13.6 million during Q4 2023.
- Its 3-year average for Amortization of Deferred Charges is $2.0 million, with a median of $2.3 million in 2022.
- Within the past 5 years, the most significant YoY rise in Cytokinetics' Amortization of Deferred Charges was 42984.62% (2023), while the steepest drop was 135082.72% (2023).
- Quarter analysis of 3 years shows Cytokinetics' Amortization of Deferred Charges stood at $1.1 million in 2022, then plummeted by 1350.83% to -$13.6 million in 2023, then soared by 125.95% to $3.5 million in 2024.
- Its Amortization of Deferred Charges stands at $3.5 million for Q4 2024, versus $3.5 million for Q3 2024 and $2.7 million for Q2 2024.